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Acute viral hepatitis (AVH) due to HCV infectionhas nowadays changed its pattern of presentationand clinical course. Posttransfusion AVH, with a
chronicity rate of up to 86%,1 has disappeared from the
Western world, where at present themajority of cases seen
in practice, referred to as “community-acquired sporadic
infection”, are acquired by intravenous drug use (IVDU)
or by non-apparent parenteral exposure due to sexual con-
tact or medical and cosmetic procedures. Contagion
through the latter modalities tends to cause a clinically
symptomatic illness with jaundice, with a self-limited
course in the majority of cases2; the clinical expression of
disease depends mostly upon host factors.3 Overall, overt
AVH due to sporadic HCV infection has a reported rate
of chronicity of about 50%, clearly lower than the post-
transfusion cases. Whether the different rate of progres-
sion to chronic infection is due to the smaller size of the
inoculum4 or other inapparent cofactors is unclear,3 re-
gardless of whether the need for immediate treatment of
all acute cases is decreased.
The epidemiology of acute hepatitis C is also changing,
affecting mostly injection drug users, who are less suitable
to undergo treatment.5 Also, some studies indicate that
even in countries where genotype 1 is prevalent, many
patients with acute hepatitis C have genotype 3 infection,
which has a higher trend to spontaneous resolution6,7 and
a response rate in excess of 80 % even on short treatment
courses.8,9 Thus, it would seem reasonable to defer treat-
ment in acute AVH because of genotype 3.
Last but not least, diagnosis of acute HCV infection
may be problematic, because serological markers cannot
reliably distinguish acute hepatitis C from an exacerba-
tion of chronic HCV infection. Although serial assess-
ment of IgM anti-HCV titres may help,10 this test is not
readily available, and only evaluation of the viral kinetics
in the ﬁrst weeks after presentation is really predictive of
spontaneous clearance.11
Since 2001, when a cohort study by Jaeckel et al.12
demonstrated that 6 months of treatment with standard
IFN alfa 2b at doses comparable to those used for chronic
hepatitis was enough to eradicate HCV infection in 98%
of patients with acute hepatitis C, the issue of optimal
treatment of AVH due to HCV has been a matter of hot
debate. Albeit a fair number of studies (reviewed by meta-
analysis in 13) show a net beneﬁt of IFN therapy over no
treatment in terms of duration of viraemia, rate of chro-
nicity, and duration of biochemical alterations, there is
still no consensus on whom to treat and the timing of
treatment. This is reﬂected by a lack of precise recommen-
dations in the most recent consensus statements from the
NIH14 and EASL.15
Large randomized trials should form the basis of guide-
lines for clinical management and treatment, and have
been advocated,16 but will probably never be performed
owing to the complexity of the population to be studied,
the rarity of this condition, the acute nature of disease,
and also the attitude favouring early treatment of many
clinicians.
In this issue of HEPATOLOGY, Wedemeyer and col-
leagues17 report the ﬁnal results of an open, uncontrolled
multicenter trial of early monotherapy of PEG IFN alfa
2b as treatment for acute hepatitis C. They evaluated 89
patients with acute hepatitis C collected from 53 different
German centers and coordinated within the network of
the HEP-NET Study House. Infection in these patients
was caused by intravenous drug abuse, sexual transmis-
sion, medical procedures, needlestick injuries and other
potential modes (tattooing, acupuncture), 2/3 of cases
being infected by HCV genotype 1. All patients in the
study received PEG IFN alfa 2b at a dose of 1.5 g/kg
once weekly for 6 months. Treatment was initiated after
an average of 76 days (range 14-150 days) from the pre-
sumed exposure, although no mention is made of the
interval between clinical presentation and the start of
therapy3).
Surprisingly, the results obtained were worse than
those of Jaeckel et al.12 In fact, an end-of-treatment re-
sponse (ETR), was reached by 82% of all patients, and
only 71% had a sustained virological response (SVR). By
comparison, Jaeckel et al.12 treated 44 patients from 24
centers with 5 MU of IFN alfa 2b daily for 4 weeks and
then twice weekly for 20 weeks obtained an ETR of 98%
and an SVR of 98%. Use of the induction dosage in
Jaeckel’s study obtained an early viral clearance at 4 weeks
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of therapy in 72% of patients. No data at 4 weeks are
available from the Wedemeyer study, but the low rate of
response appears to be mostly due to a high rate of non-
adherence to the study protocol: 21% (19/89) of the pa-
tients did not take at least 80% of the intended PEG IFN
dosage for 80% of the scheduled period, many of them
being actually lost from the study either during treatment
(8/19) or during follow-up (5/19). If the response rate was
evaluated not by intention-to-treat, but per protocol, the
rates of EVR and SVR increased to 94% and 89%, respec-
tively. Further analysis19 shows that the major determi-
nant of loss to follow-upwas a low social backgroundwith
contact to the drug scene, but not direct drug abuse.
This trial highlights well the difﬁculties facing clini-
cians who wish to perform trials of treatment of this con-
dition. Regarding the enrollment, it took 3 years and 53
centers, to recruit 89 patients. It is possible that a sizable
number of potential candidates were not enrolled into the
study because of projected non-compliance or HIV coin-
fection. Some patients with “uncertain diagnosis” may
have been excluded, whereas others may have been in-
cluded even though they had chronic infection owing to
the tight time frame preventing conﬁrmatory testing.
Another relevant issue is the number of patients treated
at each center: because the average number of subjects per
center was 1.7, many sites must have actually enrolled
only one case. Variations in follow-up protocol and phy-
sician’s experience might account for the high number of
dropouts. It is notable, however, that in the Jaeckel’s
study, where each center had enrolled on average 1.8 pa-
tients, only 1 of 44 patients did not adhere to the proto-
col. Because a number of centres were involved in both
studies, and the patient populations have similar sociode-
mographic features, it is unclear what caused the differ-
ence in compliance.
The large number of dropouts in Wedemeyer’s study
also causes problems in the interpretation of results. It is
not clear if those 19 (21%) who did not fulﬁll the criteria
of adherence to treatment, were comparable to the 70
who managed to stay on schedule. In fact, their different
socioeconomic background19 may by itself be a determi-
nant of a worse outcome. Thus, the results of this study
may not be generalizable.
In this study, IVDUs accounted for 22% of the popu-
lation, and half of them were lost to follow-up. As previ-
ously shown by Broers,5 IVDUs have a low tolerance and
adherence to IFN regimens, especially for women or for
those with ongoing drug abuse. IVDUs are fragile pa-
tients; IFN therapy for acute hepatitis may be associated
with a high incidence of psychiatric side effects leading to
treatment interruption and adverse psychosocial out-
comes. The rationale to treat IVDUs in the acute phase
must hence be very carefully weighed against the likeli-
hood of spontaneous resolution.
When, whom, and how to start treatment remains a
core issue.21 Trials performed between 1991 and 2002
were highly heterogeneous in this respect, as treatment
was started at widely variable intervals after the clinical
onset of AVH. In order to overcome heterogeneity, we
have performed a meta-analysis of controlled trials13 to
deﬁne the best timing and the optimal treatment strategy
to avoid chronicity of HCV infection while reducing
treatment to a minimum. Twelve trials were analyzed
(414 patients). The overall rate of chronicity in untreated
subjects was very high, ranging from 65% to 75%, due to
the high number of cases with posttransfusion hepatitis
included. IFN signiﬁcantly increased the SVR (risk dif-
ference 49%; 95%CI 32.9%-65%) compared to no treat-
ment. The risk difference of SVR increased from 5% to
90% when trials were ordered by increasing interferon
weekly dose. A daily induction dose during the ﬁrst
monthwas the best option of treatment.Delaying therapy
by 8 to 12 weeks after the onset of disease did not com-
promise the SVR rate.
Given that starting treatment at a slightly later stage of
acute infection does not seem to compromise the ultimate
rate of SVR, the key point is whether all patients with
acute hepatitis C should receive immediate treatment or if
a “wait and see” strategy should be adopted to identify
subjects with spontaneous viral clearance. Santantonio et
al.,22 in a prospective long-term study of 16 untreated
patients, observed that the rate of chronicity was higher in
asymptomatic than in symptomatic patients and that in
most instances spontaneous viral clearance occurs within
8 to 12 weeks from the onset of the disease. These data
support the observations made by Gerlach and Hofer2 of
a close relationship between a more severe, symptomatic
clinical course and a better likelihood of early spontane-
ous viral clearance.
Nomura et al.22 recently reported a randomized con-
trolled trial of 30 patients with acute hepatitis C. Patients
in the early-intervention group received, 8 weeks after the
onset of acute hepatitis, IFN alfa n3 6 MU daily for 4
weeks, while therapy (IFN alfa n3 6 MU daily for 4 to 20
weeks) was initiated after 1 year of observation in the
late-intervention group or in case of recrudescence of dis-
ease in the early-intervention group. The SVR rate was
signiﬁcantly higher in the early-intervention group (87%,
13 of 15 patients after short-term therapy alone, and
100% after follow-up retreatment) than in the late-inter-
vention group (53%, 8 of 15 patients after short-term
therapy with or without follow-up therapy). Thus this
trial, in accordance with our meta-analysis,13 shows that
delaying therapy up to 8 weeks after onset does not affect
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the SVR rate. Delaying the start of therapy would in fact
avoid unnecessary treatment of those patients who would
spontaneous clear the virus. In fact, among 15 consecutive
patients with acute hepatitis C observed over the last 2
years at our Unit, all with an iatrogenic exposure and
documented anti-HCV seroconversion, 11 patients
(73.3%) cleared spontaneously HCV within 12 (mean
10.4) weeks (unpublished data). In Wedemeyer’s study,
treatment was initiated after a median of 76 days after
infection (range 14-150). Assuming a median of 46 days
between exposure and ﬁrst elevation of ALT,3 the time
interval reported suggests that early treatment was initi-
ated in most cases without any “wait and see” strategy. In
the absence of an untreated control group, it is impossible
to know what is the real gain in terms of viral clearance
obtained by IFN treatment.
Ideally, one would like to treat an acute condition with
the shortest possible schedule. Unfortunately, Wedemey-
er’s study was non-contributory. Regarding duration,
data from meta-analyses of trials would indicate that ei-
ther 12 weeks 24 or 16 to 24 weeks13 of treatment with
IFN monotherapy are the best choice, whereas the more
recent trial by Nomura et al.23 suggests that short-term (4
weeks) IFN treatment of patients with acute hepatitis C
may be associated with satisfactory results, if initiated at
an early stage of the disease. Whether ethnic differences
and the use of different types of IFNs may account for the
good response is unclear. As to the issue of dosing, higher
amounts of IFN during the ﬁrst weeks of therapy seem to
be the most effective approach. In the trial by Jaeckel et
al.,12 a regimen of 5 MU of IFN once a day for 4 weeks
followed by 5 MU of IFN twice weekly for 20 weeks
achieved SVR in almost all patients. Similar results were
obtained by Delwaide et al.,25 who used the same high
induction dose. Our meta-analysis13 provides further ev-
idence that treatment with a daily dose of standard IFN is
the best option for obtaining a SVR. All these studies have
used non-pegylated IFN alfa and tried to optimize phar-
macodynamics by giving it daily. The real issue, in the age
of PEG IFNs, is whether results can be reproduced by
once-weekly regimens. Comparability of dosages between
standard and PEG IFNs is also a matter of concern.26
Before Wedemeyer’s study, at least three trials of treat-
ment of acute hepatitis C with Peg-IFN alfa 2b 1.5g/kg
per week for 12 to 24 weeks5,27,28 have been reported over
the last 2 years. The rate of SVR ranged from 57%,5 in a
study with the highest rate of non-compliance to 71%28
and 94%27 on a 24weeks regimen. In all studies, genotype
2 or 3 was the most important factor of response in ad-
herent patients. Wedemeyer’s reported SVR rate of 82%
ﬁts into this range, conﬁrming that the PEG IFNs, with
their ease of use and a response rate which is comparable
overall to standard IFNs, are currently the best therapeu-
tic option for acute hepatitis C. It still remains to be
assessed if it is possible to use less IFN, either from incep-
tion or after the ﬁrst 4 weeks. Lower dose may be of
outmost importance, since one of the main reasons for
non-adherence in Wedemeyer’s group of patients were
psychiatric symptoms, usually linked to the use of high
doses of IFN.
Will the combination with ribavirin help to raise the
SVR? Data from a small study29 with standard IFN with-
out or with ribavirin do not suggest any improvement in
efﬁcacy. Other ongoing studies (Santantonio, personal
communication) show a similar trend. Becausethe rate of
SVR to monotherapy is already very high in patients who
comply to an adequate regimen, it is unlikely that the
addition of ribavirin, a drug whose side effects are a major
reason for non adherence when treating chronic hepatitis
C, will improve the results in patients with AVH. Theo-
retically, combination therapy could be desirable for dif-
ﬁcult-to-treat genotypes or for those with HIV
coinfection.20
In conclusion, there are still more questions than an-
swers. In general, IFN monotherapy for acute hepatitis C
can be supported, but a strategy taking into account both
baseline (clinical presentation, genotype, HIV coinfec-
tion) and early (spontaneous viral decay) virological re-
sponse should be developed from carefully conducted,
controlled prospective studies comparing a “wait and see
strategy”,30 and different schedules of PEG IFN mono-
therapy to optimize adherence and costs and to reduce the
number needed to treat. The price of the ultimate success
of therapy for AVH due to HCV, i.e., a stable and deﬁn-
itive clearance ofHCVwith no residual liver disease in the
long term,31 should not be paid by a high number of
patients who are treated needlessly.
ANTONIO CRAXı`
ANNA LICATA
GI & Liver Unit, University of Palermo
Italy
References
1. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. East
German Hepatitis C Study Group. Outcome in a hepatitis C (genotype
1b) single source outbreak in Germany—a 25-year multicenter study.
J Hepatol 2005;43:590-598.
2. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsen-
heimer A, et al. Acute hepatitis C: high rate of both spontaneous and
treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
3. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dock-
ter J, et al. Viral and host factors in early hepatitis C virus infection.
HEPATOLOGY 2005;42;86–92.
4. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G,Melpolder JC, et al. The
outcome of acute hepatitis C predicted by the evolution of the viral qua-
sispecies. Science 2000 14;288:339-344.
HEPATOLOGY, Vol. 43, No. 2, 2006 CRAXI AND LICATA 223
5. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A,
Negro F. Swiss Association for the Study of the Liver (SASL 18). Barriers to
interferon-alpha therapy are higher in intravenous drug users than in other
patients with acute hepatitis C. J Hepatol 2005;42:323-328.
6. Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, et al. Hepatitis C
viral genotype inﬂuences the clinical outcome of patients with acute post-
transfusion hepatitis C. J Med Virol 2001;65:505-509.
7. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP,
Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C
virus genotype 3 infection. J Med Virol 2004;73:387-391.
8. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al.
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2
or 3. N Engl J Med 2005;352:2609-2617.
9. vonWagnerM,HuberM, Berg T, HinrichsenH, Rasenack J, Heintges T,
et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in
patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;
129:522-527.
10. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V,
et al. Diagnosis of hepatitis C virus related acute hepatitis by serial deter-
mination of IgM anti-HCV titres. J Hepatol 2005;42:646-651.
11. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-
Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis
C can be predicted by repeated measurements of serum viral load. HEPA-
TOLOGY 2003;37:60-64.
12. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel
M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl
J Med 2001;345:1452-1457.
13. Licata A, Di BonaD, Schepis F, Shahied L, Craxi A, CammaC.When and
how to treat acute hepatitis C? J Hepatol 2003;39:1056-1062.
14. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH
Consens State Sci Statements. 2002;19(Jun 10–12):1-46.
15. Proceedings of the European Association for the Study of the Liver (EASL)
International Consensus Conference on Hepatitis B. September 14–16,
2002. Geneva, Switzerland. J Hepatol 2003;39(Suppl 1):S1-S235.
16. Zekry A, Patel K, McHutchison JG. Treatment of acute hepatitis C infec-
tion: more pieces of the puzzle? J Hepatol 2005;42:293-296.
17. Wedemeyer H,Wiegand J, Buggisch P, BoecherW, Zeuzem S, Gelbmann
C, et al. Earlymonotherapy with peginterferon alfa-2b for acute hepatitis C
infection: The HEP-NET Acute-HCV-II Study. HEPATOLOGY 2006;43:
250-256.
18. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC,
et al. A randomized, double-blind trial comparing pegylated interferon
alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
HEPATOLOGY 2001;34:395-403.
19. Wiegand J, Buggisch P, BoecherW, Zeuzem S, GelbmannC, Berg T, et al.
Relevance of adherence in the treatment of acute hepatitis C infection: ﬁnal
results of the GermanHEP-NETAcute Hepatitis C II Trial. HEPATOLOGY
2005;42(Suppl 1);647A.
20. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et
al.Transmission of hepatitis C virus amongHIV-positive homosexual men
and response to a 24-week course of pegylated interferon and ribavirin. J
Acquir Immune Deﬁc Syndr 2005;40:41-46.
21. Wedemeyer H, Jackel E, Wiegand J, Cornberg M, Manns MP. Whom?
When? How? Another piece of evidence for early treatment of acute hep-
atitis C. HEPATOLOGY 2004;39:1201-1203.
22. Santantonio T, Sinisi E, Guastadisegni A, Casalino C,MazzolaM, Gentile
A, et al. Natural course of acute hepatitis C: a long-term prospective study.
Dig Liver Dis 2003;35:104-113.
23. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al.
Short-term interferon-alfa therapy for acute hepatitis C: a randomized
controlled trial. HEPATOLOGY121 2004;39:1213-9.
24. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999;
31(Suppl 1):189-192.
25. Delwaide J, Bourgeois N, Gerard C, DeMaeght S, Mokaddem F,Wain E,
et al. Treatment of acute hepatitis C with interferon alpha-2b: early initi-
ation of treatment is the most effective predictive factor of sustained viral
response. Aliment Pharmacol Ther 2004;20:15-22.
26. Vyas K, BrassardDL,DeLorenzoMM, Sun Y,GraceMJ, Borden EC, et al.
Biologic activity of polyethylene glycol12000-interferon-alpha2b com-
pared with interferon-alpha2b: gene modulatory and antigrowth effects in
tumor cells. J Immunother 2003;26:202-211.
27. Santantonio T, FasanoM, Sinisi E, Guastadisegni A, Casalino C, Mazzola
M, et al. Efﬁcacy of a 24-week course of PEG-interferon alpha-2b mono-
therapy in patients with acute hepatitis C after failure of spontaneous
clearance. J Hepatol 2005;42:329-333.
28. Talleri G, Cariti G, Gaiottino F, De Rosa F, De Blasi T, Audagnotto S, et
al. Three months course of PEG IFN alfa 2b in acute HCV hepatitis
[Abstract]. HEPATOLOGY 2004;40(Suppl 1);179A.
29. Rocca P, Bailly F, Chevallier M, Chevallier P, Zoulim F, Trepo C. Early
treatment of acute hepatitis C with interferon alpha-2b or interferon al-
pha-2b plus ribavirin: study of sixteen patients Gastroenterol Clin Biol
2003;27:294-299.
30. Pimstone NR, Pimstone D, Saicheur T, Powell J, Yu AS. “Wait-and-see”:
an alternative approach to managing acute hepatitis C with high-dose
interferon-alpha monotherapy. Ann Intern Med 2004;141:W91-W92.
31. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J,
et al. Long-term follow-up after successful interferon therapy of acute
hepatitis C. HEPATOLOGY 2004;40:98-107.
224 CRAXI AND LICATA HEPATOLOGY, February 2006
